CollPlant Biotechnologies (CLGN) Receivables - Other (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Receivables - Other came in at $50000.0 in Q3 2023, up 176.92% YoY from $18055.6 in Q3 2022, and down 62.96% on a QoQ basis from $135000.0 in Q1 2023.
CollPlant Biotechnologies (CLGN) Receivables - Other (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 7 years of Receivables - Other data on file, last reported at $50000.0 in Q3 2023.
- Quarterly Receivables - Other rose 176.92% year-over-year to $50000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $50000.0 (up 176.92% YoY) and the FY2022 annual result came in at $119000.0, up 164.32% from the prior year.
- Receivables - Other fell to $50000.0 in Q3 2023, from $135000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $5.2 million in Q1 2019 to a low of -$740000.0 in Q2 2021.
- A 5-year average of $201176.5 and a median of -$28000.0 in 2021 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2021 — Receivables - Other slumped 696.77% — and 2022, when it surged 675.0%.
- Tracing CLGN's Receivables - Other over 5 years: stood at $35000.0 in 2019, then fell by 11.43% to $31000.0 in 2020, then tumbled by 696.77% to -$185000.0 in 2021, then soared by 35.68% to -$119000.0 in 2022, then surged by 142.02% to $50000.0 in 2023.
- The last three Receivables - Other figures came in at $50000.0 (Q3 2023), $135000.0 (Q1 2023), and -$119000.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 210,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Dec 31, 2024 | -40,000.00 |
| Dec 31, 2024 | -40,000.00 |
| Dec 31, 2023 | 150,000.00 |
| Dec 31, 2023 | 150,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 135,000.00 |
| Mar 31, 2023 | 135,000.00 |
| Dec 31, 2022 | -119,000.00 |
| Dec 31, 2022 | -119,000.00 |
| Sep 30, 2022 | -65,000.00 |
| Sep 30, 2022 | -65,000.00 |
| Jun 30, 2022 | -170,000.00 |
| Jun 30, 2022 | -170,000.00 |
| Mar 31, 2022 | 161,000.00 |
| Mar 31, 2022 | 161,000.00 |
| Dec 31, 2021 | -185,000.00 |
| Dec 31, 2021 | -185,000.00 |